{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:44:35Z","timestamp":1793144675098,"version":"4.5.0"},"reference-count":34,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2006,8,8]],"date-time":"2006-08-08T00:00:00Z","timestamp":1154995200000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Basic Clin Pharma Tox"],"published-print":{"date-parts":[[2006,8]]},"abstract":"<jats:p><jats:bold>Abstract:<\/jats:bold> Phenytoin dosing is critical in cancer patients as to decreased absorption secondary to chemotherapy\u2010induced gastrointestinal toxicity, increased phenytoin metabolism in the liver secondary to chemotherapy, extreme patient profile that falls outside the predicted pharmacokinetic population, frequent hypoalbuminaemia and polydrug treatment. A retrospective study to assess the variability of free phenytoin and the free fraction of phenytoin, as well as the influence of comedication on these parameters was performed in cancer patients by using a population approach. Two hundred fifty\u2010eight data pairs of total phenytoin and free phenytoin were analysed from 155 cancer patients on stable phenytoin using non\u2010linear mixed\u2010effect modeling (NONMEM). Total and free phenytoin were determined using a fluorescence polarization immunoassay. An extensive model building procedure was subsequently used for covariate testing on the free fraction of phenytoin. Mean total phenytoin concentration was 11.7 mg\/l, free phenytoin 1.25 mg\/l and phenytoin free fraction 0.107. Free phenytoin was &lt;1 mg\/l on 132 occasions (51.2%) and &gt;2 mg\/l on 37 occasions (14.3%). Total and free phenytoin were significantly correlated (r<jats:sub>S<\/jats:sub>=0.827, P&lt;0.01). The free fraction of phenytoin was independent of time after drug intake. Serum albumin concentrations and comedication with valproic acid or carbamazepine were identified by NONMEM as significant determinants of phenytoin free fraction. Co\u2010medication with valproic acid and carbamazepine led to a 52.5% and 38.5% increase of the free fraction of phenytoin, respectively, and a 10 g\/l decrease of serum albumin to a 15.1% increase of the free fraction of phenytoin. Phenytoin pharmacokinetics could reliably be estimated from oral doses and steady\u2010state concentrations of protein\u2010bound and free phenytoin. The variability in the free fraction of phenytoin could partly be explained by the influence of albumin concentrations and antiepileptic comedication. Significant alterations of the free fraction of phenytoin and free phenytoin by co\u2010administration of valproic acid or carbamazepine suggest therapeutic drug monitoring of free phenytoin to be of potential benefit in cancer patients.<\/jats:p>","DOI":"10.1111\/j.1742-7843.2006.pto_309.x","type":"journal-article","created":{"date-parts":[[2006,8,8]],"date-time":"2006-08-08T19:46:02Z","timestamp":1155066362000},"page":"133-140","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Interactions of Serum Albumin, Valproic Acid and Carbamazepine with the Pharmacokinetics of Phenytoin in Cancer Patients"],"prefix":"10.1111","volume":"99","author":[{"given":"Markus","family":"Joerger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. D. R.","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Boogerd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J.","family":"Van Der Sande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. H. M.","family":"Schellens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. H.","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,8,8]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-198706000-00002"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200206000-00009"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2002.121829"},{"key":"e_1_2_6_5_1","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/clinchem\/46.8.1132","article-title":"Evidence\u2010based implementation of free phenytoin therapeutic drug monitoring","volume":"46","author":"Burt M.","year":"2000","journal-title":"Clin. Chem."},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/106002809603000516"},{"key":"e_1_2_6_7_1","first-page":"143","article-title":"Management of seizures in the adult patient with cancer","volume":"3","author":"Gilbert M. R.","year":"1995","journal-title":"Cancer Pract."},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI108035"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-198903000-00003"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/106002809302701114"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1974153276"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200410000-00012"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1984.tb02387.x"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011579109640"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1211\/0022357991773474"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1991.tb04300.x"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.2510140409"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-3019(81)80054-7"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1985.tb05406.x"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200207000-00007"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1988.45"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1982.tb01981.x"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199109000-00004"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1975.00490470042005"},{"key":"e_1_2_6_25_1","first-page":"24","article-title":"Binding parameters of phenytoin during monotherapy and polytherapy","volume":"30","author":"Pospisil J.","year":"1992","journal-title":"Int. J. Clin. Pharmacol. Ther. Toxicol."},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1995.tb00494.x"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199508000-00002"},{"key":"e_1_2_6_28_1","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1177\/106002809502900918","article-title":"Effect of dexamethasone on the decrease of serum phenytoin concentrations","volume":"29","author":"Recuenco I.","year":"1995","journal-title":"Ann. Pharmacother."},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1984.tb05007.x"},{"key":"e_1_2_6_30_1","first-page":"407","volume-title":"Clinical pharmacokinetics \u2013 Concepts and applications","author":"Rowland M.","year":"1995"},{"key":"e_1_2_6_31_1","first-page":"425","article-title":"Dexamethasone\/phenytoin interactions: neurooncological concerns","volume":"132","author":"Ruegg S.","year":"2002","journal-title":"Swiss Med. Wkly."},{"key":"e_1_2_6_32_1","first-page":"545","article-title":"Serum protein binding of phenytoin, diazepam and propranolol in chronic renal diseases","volume":"25","author":"Tiula E.","year":"1987","journal-title":"Int. J. Clin. Pharmacol. Ther. Toxicol."},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/106002809002401002"},{"key":"e_1_2_6_34_1","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1001\/jama.1985.03360150038012","article-title":"Phenytoin\u2010dexamethasone: a possible drug\u2010drug interaction","volume":"254","author":"Wong D. D.","year":"1985","journal-title":"J. Amer. Med. Ass."},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-198503000-00008"}],"container-title":["Basic &amp; Clinical Pharmacology &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-7843.2006.pto_309.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1742-7843.2006.pto_309.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T19:27:56Z","timestamp":1696966076000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-7843.2006.pto_309.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["10.1111\/j.1742-7843.2006.pto_309.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1742-7843.2006.pto_309.x","archive":["Portico"],"relation":{},"ISSN":["1742-7835","1742-7843"],"issn-type":[{"value":"1742-7835","type":"print"},{"value":"1742-7843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8]]},"assertion":[{"value":"2006-08-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}